1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Germany to receive 3.8 mln doses of Novavax's new COVID vaccine in Q1

01/25/2022 | 04:31am EDT

BERLIN, Jan 25 (Reuters) - Germany expects to receive 3.8 million doses of Novavax's newly approved COVID-19 vaccine Nuvaxovid by March 20, the health ministry said on Tuesday, as the government looks to persuade unvaccinated Germans to get a shot.

Germany will receive 1.4 million doses in the week of Feb. 21 and should receive the rest of the 3.8 million doses in the subsequent few weeks.

Novavax is expected to deliver 34 million doses to Germany this year. The shipment is a part of the U.S. drugmaker's deal to supply up to 200 million doses to the European Union's 27 member states.

Novavax's protein-based vaccine, which was approved by the European Medicines Agency (EMA) in December, uses alternative technology to the vaccines from Pfizer-BioNTech, , Moderna, AstraZeneca and J&J .

This could convince reluctant Germans, sceptical about the novel mRNA technology and its long-term effects, to take Novavax's more traditional vaccine and boost Germany's vaccination rate, which is lower than other western European countries.

Data from two large studies showed the vaccine has an efficacy rate of around 90% and the firm said early data showed it was effective in generating an immune response against the more infectious Omicron variant. (Reporting by Riham Alkousaa and Andreas Rinke; editing by Jason Neely)

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.31% 10248 Delayed Quote.18.11%
BIONTECH SE 6.88% 167.87 Delayed Quote.-34.88%
MODERNA, INC. 4.12% 143.38 Delayed Quote.-43.55%
NOVAVAX, INC. 12.13% 58.43 Delayed Quote.-59.16%
PFIZER, INC. 0.50% 50.65 Delayed Quote.-14.23%
All news about NOVAVAX, INC.
05/16Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan
05/11TRANSCRIPT : Novavax, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-..
05/11SECTOR UPDATE : Health Care Stocks Edging Lower Ahead of Wednesday Close
05/11SECTOR UPDATE : Health Care Stocks Still Hanging on for Small Advance
05/11B. Riley Lowers Novavax's Price Target to $181 from $203, Keeps Buy Rating
05/10Wall St slips in choppy trading ahead of inflation data
05/10GLOBAL MARKETS LIVE : Bayer, Sony, AMC, Peloton, Tesla...
05/10Novavax Reports Higher Q1 Results; Shares Slump
05/10WALL STREET STOCK EXCHANGE : A little respite for Wall Street
05/10SECTOR UPDATE : Health Care Stocks Climb Premarket Tuesday
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 4 285 M - -
Net income 2022 1 969 M - -
Net cash 2022 2 508 M - -
P/E ratio 2022 2,45x
Yield 2022 -
Capitalization 4 565 M 4 565 M -
EV / Sales 2022 0,48x
EV / Sales 2023 0,38x
Nbr of Employees 1 541
Free-Float 99,0%
Duration : Period :
Novavax, Inc. Technical Analysis Chart | NVAX | US6700024010 | MarketScreener
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 6
Last Close Price 58,43 $
Average target price 174,83 $
Spread / Average Target 199%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-59.16%4 565
MODERNA, INC.-43.55%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-28.50%37 337
SEAGEN INC.-7.74%26 323